Skip to main content
. 2023 Aug 28;16:100. doi: 10.1186/s13045-023-01497-3

Table 5.

The clinical trials of VEGF/VEGFR inhibitors in TNBC

Drug name Com Num Regiments Ph State Object POM NCT number
Bevacizumab 54 15 mg/ kg II Completed mTNBC PFS NCT03577743
Bevacizumab 2591 5 mg/kg q1w III Completed TNBC IDFS NCT00528567
Bevacizumab Albumin-bound paclitaxel 128

Bevacizumab: 7.5 mg/kg iv q3w

Albumin-bound paclitaxel: 260 mg/m2 iv q3w

 II Recruiting mTNBC PFS NCT05192798
Bevacizumab Tirelizumab 15

Bevacizumab: 7.5 mg/kg iv q3w

Tirelizumab: 200 mg iv q3w

 II Recruiting mTNBC ORR NCT05303038
Bevacizumab Liposomal doxorubicin hydrochloride/ Everolimus 17

Bevacizumab: iv over 90 min on day 1

Liposomal doxorubicin hydrochloride: iv over about 3 h on day 1

Everolimus: po qd on days 1–21

 II Active, not recruiting Advanced TNBC pCR NCT02456857
Bevacizumab Paclitaxel/ Docetaxel 49

Bevacizumab: 10 mg/kg iv q2w

Paclitaxel q1w or docetaxel q3w

 IV Completed TNBC PFS NCT01094184
Bevacizumab Docetaxel, Carboplatin 45

Bevacizumab: 7.5 mg/kg iv q3w

Docetaxel iv and carboplatin iv

 II Completed TNBC pCR NCT01208480
Bevacizumab Nab-paclitaxel, erlotinib 59

Bevacizumab: iv over 30–90 min on days 1,15

Nab-paclitaxel: iv on days 1, 8, and 15

erlotinib hydrochloride: po qd

 II Completed TNBC PFS NCT00733408
Bevacizumab Abraxane, Carboplatin 41

Bevacizumab: 10 mg/kg iv on days 1,15

Abraxane: 100 mg/m2 iv over 30 min on days 1,8,15

Carboplatin: AUC = 2 iv over 15 min on days 1,8,15

 II Completed mTNBC CBR NCT00479674
Apatinib Camrelizumab 58

Apatinib:250 mg po qd

Camrelizumab: 200 mg iv on day 1

 II Recruiting TNBC pCR NCT05556200
Apatinib Camrelizumab and nab-paclitaxel 35

Apatinib:250 mg po qd

Camrelizumab: 200 mg iv q2w

Nab-paclitaxel: 125 mg/m2 iv q1w

 II Not yet recruiting TNBC pCR NCT05447702
Apatinib Paclitaxel and Carboplatin 29

Apatinib: 250 mg po qd on day 1-14

Paclitaxel: 175 mg/m2 on day 1

Carboplatin: AUC = 4 on day 1,14

 II Unknown TNBC pCR NCT03735082
Apatinib Capecitabine 80

Apatinib: 425 mg on day 1-21

Capecitabine: 1000 mg/m2 bid on day 1-14

 II Recruiting Advanced TNBC PFS NCT03775928
Apatinib Paclitaxel 20

Apatinib: 500 mg po qd 12 weeks

Paclitaxel: 80 mg/m2 on day 1 q1w

 II Recruiting Advanced TNBC ORR NCT03348098
Apatinib Albumin paclitaxel and carboplatin 60

Apatinib: 250 mg po on day 1–21

Albumin paclitaxel: 260 mg/m2 iv on day 1 Carboplatin: AUC = 5–6 iv on day 1

 II Recruiting TNBC pCR NCT03650738
Apatinib Camrelizumab and Eribulin 46

Apatinib: 250 mg/d po on day 1-21

Camrelizumab: 200 mg iv q3w

Eribulin: 1.4 mg/m2 iv on day 1, 8 q3w

 II Active, not recruiting Advanced TNBC ORR NCT04303741

mTNBC: metastatic triple negative breast cancer; PFS: progression-free survival; IDFS: invasive disease-free survival; ORR: overall response rate; pCR: pathologic complete response; CBR: clinical benefit rate